Trial Profile
Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary) ; Caspofungin
- Indications Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
- 06 Jul 2019 Results of post hoc pooled analysis determining the efficacy and safety of anidulafungin treatment in patients with intra abdominal candidiasis from five prospective studies (NCT00496197, NCT00548262, NCT00537329,NCT00689338 and NCT00805740) published in the European Journal of Clinical Microbiology and Infectious Diseases
- 17 Apr 2014 New trial record